Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 5, 2009, Pages 325-329

  Chantada, Guillermo L ^a,d   Gonzalez, Andrea ^a   Fandino, Adriana ^a   De Davila, Maria T G ^a   Demirdjian, Graciela ^b   Scopinaro, Marcelo ^a   Abramson, David ^c  

^a Department of Hemato oncology ^*  (Argentina)

^b HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Department of Hematooncology   (Argentina)

Author keywords

Clinical presentation; Glaucoma; Prognostic factors; Retinoblastoma

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; METHOTREXATE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ARTICLE; BUPHTHALMOS; CHILD; CHOROID; CLINICAL FEATURE; CONTROLLED STUDY; ENUCLEATION; GLAUCOMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OPTIC NERVE; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; RISK FACTOR; SCHOOL CHILD; SCLERA; SENSITIVITY AND SPECIFICITY; CHOROID TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RETINA TUMOR; RETROSPECTIVE STUDY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHOROID NEOPLASMS; HUMANS; HYDROPHTHALMOS; INFANT; NEOPLASM, RESIDUAL; OPTIC NERVE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERA; SENSITIVITY AND SPECIFICITY;

EID: 66149120677     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181923cc5     Document Type: Article

References (24)

1. Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24:828-848.
2. Chantada GL, Dunkel IJ, de Davila MT, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069-1073.
3. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923-931.
4. Chantada GL, Doz F, Orjuela M, et al. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer. 2008;50:692-694.
5. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1996;77:1206-1213.
6. Chantada G, Doz F, Antoneli CB, et al. A proposal for an International Retinoblastoma Staging System. Pediatr Blood Cancer. 2006;47:801-805.
7. Schvartzman E, Chantada G, Fandino A, et al. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol. 1996;14:1532-1536.
8. Howarth C, Meyer D, Hustu HO, et al. Stage-related combined modality treatment of retinoblastoma. Results of a prospective study. Cancer. 1980;45:851-858.
9. Antoneli CB, Steinhorst F, de Cassia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98:1292-1298.
10. Bowman RJ, Mafwiri M, Luthert P, et al. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer. 2008;50: 160-162.
11. Bellaton E, Bertozzi AI, Behar C, et al. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. Br J Ophthalmol. 2003;87:327-329.
12. Armenian SH, Panigrahy A, Murphree AL, et al. Management of retinoblastoma with proximal optic nerve enhancement on MRI at diagnosis. Pediatr Blood Cancer. 2008;51:479-484.
13. Brisse HJ, Guesmi M, Aerts I, et al. Relevance of CT and MRI in retinoblastoma for the diagnosis of postlaminar invasion with normal-size optic nerve: a retrospective study of 150 patients with histological comparison. Pediatr Radiol. 2007;37: 649-656.
14. de Graaf P, Moll AC, Imhof SM, et al. Retinoblastoma and optic nerve enhancement on MRI: not always extraocular tumour extension. Br J Ophthalmol. 2006;90:800-801.
15. Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73:692-698.
16. Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77:544-548.
17. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276-2280.
18. Grabowski EF, Abramson DH. Intraocular and extraocular retinoblastoma. Hematol Oncol Clin North Am. 1987;1: 721-735.
19. Chantada G, Fandino A, Davila MT, et al. Results of a prospective study for the treatment of retinoblastoma. Cancer. 2004;100:834-842.
20. Hadjistilianou T, De Francesco S, Marconcini S, et al. Phthisis bulbi and buphthalmos as presenting signs of retinoblastoma: a report of two cases and literature review. Eur J Ophthalmol. 2006;16:465-469.
21. Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics. 2003;112(Pt 1): 1248-1255.
22. Kao LY, Su WW, Lin YW. Retinoblastoma in Taiwan: survival and clinical characteristics 1978-2000. Jpn J Ophthalmol. 2002;46:577-580.
23. Shields CL, Shields JA, Shields MB, et al. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology. 1987;94:839-846.
24. Pe'er J, Neufeld M, Baras M, et al. Rubeosis iridis in retinoblastoma. Histologic findings and the possible role of vascular endothelial growth factor in its induction. Ophthalmology. 1997;104:1251-1258.